Skye Bioscience

At Skye Bioscience, we are dedicated to unlocking new therapeutic pathways for metabolic health. Founded in 2012, our mission has been to develop next-generation drugs aimed at treating obesity and other metabolic diseases. Our innovative approach utilizes G-protein coupled receptors to create first-in-class therapeutics that promise enhanced health outcomes for patients with significant unmet needs. Central to our strategy is nimacimab, a novel peripheral CB1 inhibitor currently undergoing clinical trials that demonstrate the effectiveness of targeting metabolic processes without central nervous system side effects. This approach not only improves drug tolerability but also aligns with growing market demands for sustainable weight loss solutions.

Our team consists of industry veterans who bring extensive experience from various sectors of life sciences, ensuring that we leverage both scientific insight and business acumen to advance our innovative therapies. Under the leadership of our CEO, Punit Dhillon, we have raised substantial capital and established key pharmaceutical partnerships. We are committed to advancing our clinical pipeline with the goal of delivering revolutionary treatments to patients. As we move forward, Skye Bioscience aims to present compelling data that supports the broad applicability of nimacimab within the obesity landscape, ultimately striving to improve patient outcomes and expand access to effective healthcare interventions.